Sun Pharma and Taro Pharmaceutical Enter into a Merger Agreement
Shots:
- Sun Pharmaceutical and Taro Pharmaceutical have signed a definitive merger agreement with Sun Pharma acquiring all outstanding ordinary shares of Taro (excl. those already held by Sun Pharma or its affiliates) for $43.00 per share in cash, without interest
- Under the merger, the purchase price of $43.00 per share represents a 48% premium over the closing price on May 25, 2023, and a 58% to the volume-weighted average price of the shares during the 60 days before and incl. May 25, 2023. It also reflects a 13% increase from the initially proposed purchase price of $38.00 per share on May 26, 2023
- Taro will become a privately held company on the completion of the merger that is anticipated in H1’24
Ref: Sun Pharma | Image: Sun Pharma
Related News:- Pharmazz and Sun Pharma Enter into Licensing Agreement to Commercialize Tyvalzi (Sovateltide) in India for Cerebral Ischemic Stroke
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
